RxDoctor Payments DataLook up a doctor →

Rama Jager, MD

Ophthalmology · Oak Forest, ILNPI 1992790182

Payments from drug & device makers

$232,221in general payments, 2019–2025

Across 66 payments — averaging $3518.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salutaris Medical Devices, Inc.$228K
  • AbbVie$3K
  • Regeneron Healthcare Solutions, Inc.$502
  • Astellas Pharma US Inc$161
  • Eyepoint US, Inc.$152
  • Genentech USA, Inc.$95
  • plus $559 from 13 others
$218,244in research payments, 2019–2025

Across 4 payments — averaging $54,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Salutaris Medical Devices, Inc.$218K

What the payments were for

  • Consulting fees$225,00099%
  • Food & beverage$1,7921%
  • Gifts$190%
  • Entertainment$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$232,221 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,379,289
Medicare patients
883
Services billed
23,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost17$10,423
Prednisolone Acetate129$5,892
CombiganBrimonidine Tartrate/Timolol16$5,730
Brimonidine Tartrate261$5,674
Latanoprost260$3,249
Ketorolac Tromethamine97$2,317
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$1,920
Azelastine Hcl11$359
Timolol Maleate26$157
Dorzolamide Hcl12$55
Acetaminophen-CodeineAcetaminophen With Codeine16$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$2,752$16,15333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Oak Forest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →